Longitudinal Evaluation and Real-world Evidence of NT201

Merz Pharmaceuticals

Status: Terminated

Conditions: Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face

Treatments: Drug: IncobotulinumtoxinA

Study type: Observational

Funder types: Industry

Identifiers

NCT05222607

M602011076

Details and patient eligibility

About

This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older.
• Planning treatment with incobotulinumtoxinA.

Exclusion criteria

• Any contraindication to treatment with incobotulinumtoxinA or any other neurotoxins.
• Currently pregnant, breastfeeding, or intending to become pregnant during study participation.
• Known hypersensitivity to incobotulinumtoxinA or any of its formulation ingredients.
• Any infection and/or inflammation at the planned injection points.
• Previous treatment with any botulinum toxin products for any aesthetic or therapeutic indications.

Trial design

11 participants in 1 patient group

Facial treatment with incobotulinumtoxinA in treatment naïve participants

Treatment:

Drug: IncobotulinumtoxinA